Findoc-cll.in/3rd_qtr_result

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 31ST DECEMBER 2013.

(Rupees in '000')

S. No.

Particulars

Un -audited

Un-audited

Audited

Quarter Ended

Nine Month Ended

Year

31.Dec.13

30.Sep.13

31.Dec.12

31.Dec.13

31.Dec.12

31.Mar.13

PART-l

(a)Income from Operation

Gross Sales

19,323

19,712

16,927

59,747

59,338

76,818

less Excise Duty

1,036

1,261

1,191

3,695

4,003

5,282

Net Sales/Income From Operation

18,287

18,451

15,736

56,052

55,335

71,536

(b) Other Operating Income

323

Total Income from Operation

18,287

18,451

16,059

56,052

55,658

71,859

Expenses

(a)

Cost Of Material Consumed

5,884

5,154

5,178

17,639

18,249

21,402

(b)

Purchase of Stock in Trade

3,503

1,344

942

6,624

4,316

5,460

(c)

Change in Inventories Of Finished Goods and Work in Progress of Stock in trade

(1,467)

1,679

(897)

227

(732)

1,702

(d)

Employee Benefit Expenses

6,730

6,614

6,709

19,555

20,182

25,748

(e)

Depreciation & Amortisation Expenses

656

657

653

1,968

1,960

2,619

(f)

Other Expenses

3,047

2,892

2,905

9,336

9,527

12,083

Total Expenses

18,353

18,340

15,490

55,349

53,502

69,014

Profit/(Loss) from Operation Before Other Income ( 1-2)

-66

111

569

703

2,156

2,845

Other Income

636

299

986

508

775

Profit /(Loss) from ordinary activities before

570

410

622

1,689

2,664

3,620

Finance Cost

270

291

474

966

1,553

2,021

Profit /(Loss) from ordinary activities after finance Cost but before Exceptional items ( 5-6)

300

119

148

723

1,111

1,599

Exceptional items

Profit /(Loss) from ordinary activities before Tax ( 7-8)

300

119

148

723

1,111

1,599

Tax Expenses ( Provision for Taxation ) Current tax

297

Deffered tax

504

Net Profit/(Loss) From Ordinary Activities after Tax (9-10)

300

119

148

723

1,111

798

Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears]

354,35

Reserves Excluding Revaluation Reserves

8,428

Earning per share (EPS) before extraordinary item( not Annualised)

i) Basic & Diluted

0.17

ii) Diluted

PART-ll

PARTICULARS OF SHAREHOLDING

Public shareholding

Number of Shares

2,894,901

2,904,901

2,894,901

2,904,901

Percentage of shareholding

63.33%

63.55%

63.33%

63.55%

Promoters and promoter group Shareholding

Pledged/Encumbered

Number of shares

Percentage of shares (as a % of the total shareholding of promoter and promoter group)

iii

Percentage of shares (as a% of the total share capital of the company)

Non-encumbered

Number of Shares

1,676,099

1,666,099

1,676,099

1,666,099

Percentage of shares (as a% of the total shareholding of promoter and promoter group)

36.67%

36.45%

36.67%

36.45%

Percentage of shares (as a % of the total share capital of the company)

100%

B.	INVESTORS COMPLAINTS	3 Months ended 31.12.2013
	Pending at Begining of the Quarter	NIL
	Received During the Quarter	NIL
	Disposed of During the Quarter	NIL
	Remaining at the end of the Quarter	NIL

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on 31-01-2014
The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
Previous period figures have been regrouped wherever required.